Human and Rat Mesangial Cell Receptors for Glucose-modified Proteins: Potential Role in Kidney Tissue Remodelling and Diabetic Nephropathy

By Edward Y. Skolnik, Zhi Yang, Zenji Makita, Steven Radoff, Martina Kirstein, and Helen Vlassara

From the Laboratory of Medical Biochemistry, The Rockefeller University, New York, New York 10021

Summary

Advanced glycosylation endproducts (AGEs) are derived from the nonenzymatic addition of glucose to proteins. AGEs have been found to accumulate on tissue proteins in patients with diabetes, and their accumulation is thought to play a role in the development of diabetic complications. The finding that macrophages and endothelial cells contain AGE-specific receptors led us to examine whether mesangial cells (MCs) also possess a mechanism for recognizing and processing AGEs. Membrane extracts isolated from rat and human MCs were found to bind AGE-bovine serum albumin (BSA) in a saturable fashion, with a binding affinity of 2.0 _+ 0.4 x 10^6 M^-1 (500 nM). The binding was specific for the AGE adduct, since AGE-modified collagen I and ribonuclease both competitively inhibited 125I-AGE-BSA binding to MC membranes, while the unmodified proteins did not compete. Binding of AGE proteins was followed by slow internalization and degradation of the ligand. Ligand blotting of MC membrane extracts demonstrated three distinct AGE-binding membrane proteins of 50, 40, and 30 kD. Growth of MCs on various AGE-modified matrix proteins resulted in alterations in MC function, as demonstrated by enhanced production of fibronectin and decreased proliferation. These results point to the potential role that the interaction of AGE-modified proteins with MCs may play in vivo in promoting diabetic kidney disease.

In diabetes mellitus, expansion of the glomerular mesangium correlates with the clinical features of diabetic kidney disease, including albuminuria, hypertension, and decreased glomerular filtration rate (1-3). Mesangial expansion leads to a decrease in glomerular filtration rate by impinging on the glomerular capillary vasculature, thereby decreasing the filtering surface of the glomerulus. The increase in mesangial matrices is due primarily to the accumulation of normal matrix proteins, including collagens type IV and type V, laminin, and fibronectin (4, 5). While it is generally agreed that the altered physical milieu in diabetes is responsible for the development of diabetic kidney disease, the mechanisms by which hyperglycemia might lead to mesangial expansion are still poorly defined.

Experimental data have accumulated linking the formation of advanced glycosylation endproducts (AGEs) to many of the complications of diabetes (6, 7). AGEs are derived from early products of nonenzymatic glycosylation, and are formed slowly from the early Amadori product after a series of reactions and rearrangements. AGEs, which represent irreversible late reacting products, are characterized by brown color, fluorescence, and their ability to cause protein-to-protein crosslinking (6, 7). AGE compounds have also been shown to bind to specific receptors on murine and human monocyte/macrophages, as well as bovine and human endothelial cells. Since AGEs form progressively as a function of time, it is hypothesized that under normal conditions, the function of AGE receptors is partly to signal cells such as the macrophage to promote turnover of aging tissue proteins and cells (8, 9). Under conditions of normoglycemia, the removal of AGE-modified proteins occurs conceivably at a rate sufficient to keep up with the production of new AGE proteins, preventing overt accumulation of AGE-modified proteins. However, in diabetes, excessive formation of AGEs in the presence of continuously elevated blood glucose may overwhelm the body's ability to remove AGEs, resulting in a net excess of AGEs on most structural tissue proteins (10). This hypothesis is supported by the demonstration that AGEs accumulate at an accelerated rate in diabetics on long-lived matrix proteins in the kidney and blood vessel wall (8, 11). Recent experimental evidence suggested that interaction of AGE-modified proteins with macrophages and endothelial

1 Abbreviations used in this paper: AGE, advanced glycosylation endproduct; EC, endothelial cell; MC, mesangial cell.
cells (ECs) can result not only in the binding and uptake of AGEs, but can also modulate cellular function (12, 13). Macrophages, upon interaction with AGEs, are induced to release the cytokines cachectin/TNF, IL-1, platelet-derived growth factor, and insulin-like growth factor I (12, 14, 15). Under conditions of normoglycemia, this response may be beneficial, aiding in the removal of AGE proteins and promoting normal tissue remodeling. However, excessive formation of AGEs in diabetics may lead to an exaggerated response, resulting in excessive production of these factors, all of which could contribute to diabetic complications such as premature development of atherosclerotic plaques or mesangial expansion in the kidney. More direct evidence supporting a role for AGE receptor interaction in the development of diabetic complications derives from experiments performed with cultured ECs (13). The interaction of ECs with AGEs induces several changes in EC function that are characteristic of diabetes, including an increase in EC permeability and an increase in EC procoagulant properties.

Since mesangial cells are primarily responsible for the maintenance of the glomerular mesangium (16, 17), we hypothesized that they may contain binding sites for AGE-modified proteins via which they may participate in the turnover of these proteins. In addition, we hypothesized that the accumulation of AGEs on mesangial matrix proteins in diabetes could directly modify mesangial cell (MC) function, resulting in altered proliferation and/or synthesis of matrix proteins. Our results indicate that MCs specifically bind AGE-modified proteins in a saturable fashion. In addition, MCs plated onto AGE-modified matrices demonstrate functional changes, including enhanced production of fibronectin and decreased proliferation. These results point to the potential role that the interaction of AGE-modified matrix proteins with native cells may play in vivo in promoting diabetic kidney disease.

Materials and Methods

Cell Culture. Primary cultures of rat MCs were obtained from outgrowths of isolated rat glomeruli by Dr. M. Ganz (Yale University, New Haven, CT), as previously described (18, 19). In brief, rats were anesthetized with ether and the kidneys were excised under sterile conditions. After removing the kidney capsule, the kidney cortices were homogenized and glomeruli were isolated after passage through a series of graded sieves. The glomeruli were then treated with bacterial collagenase (Worthington Biochemical Corporation, Freehold, NJ) at 37°C for 30 min, and after extensive washing, the glomerular remnants were plated onto tissue culture flasks in RPMI 1640, supplemented with 20% FCS, 2 mM l-glutamine, 2 mM sodium pyruvate, 5 μg/ml bovine insulin, 5 μg/ml human transferrin, 1% (vol/vol) nonessential amino acids, and gentamicin. Cellular outgrowths appeared between days 5 and 8, and all experiments were performed using cells between the fourth and tenth passage. The purity of the MC population was demonstrated as described in detail elsewhere (20). In brief, immunofluorescent staining demonstrated prominent intracellular staining for smooth muscle cell myosin, MHC class I antigen, vimentin, collagen IV, and fibronectin. The cells stained negative for Fc receptor, MHC II surface antigen, cytokerin, and factor VIII, and were able to grow in d-valine-substituted medium.

Preparation of Ligands. AGE-BSA and AGE-ribonuclease were made by incubating BSA and bovine ribonuclease (Sigma Chemical Co., St. Louis, MO) with 0.5 M glucose-6-phosphate (G-6-P), at 37°C for 4–6 wk in a 10 mM PBS buffer, pH 7.4, in the presence of protease inhibitors and antibiotics as previously described (8). Unincorporated glucose was removed by dialysis against 1× PBS. The concentration of AGE-BSA was determined by the method of Bradford (22), and the concentration of ribonuclease was determined spectrophotometrically. AGE formed on either BSA or ribonuclease was assessed based on characteristic absorption and fluorescence spectra (emission at 450 nm, excitation at 390 nm) (23) and quantitated by a radioreceptor assay using intact RAW 266.7 cells grown in 96-well plates (11, 24). According to this assay, AGE-BSA contained ~70 AGE U/mg (1 U of AGE is defined as the concentration of unknown agent required to produce 50% inhibition of standard 125I-AGE-BSA binding) and AGE-ribonuclease contained 62 AGE U/mg.

To examine the effect of early glycosylation product reduction on ligand binding, AGE-BSA was incubated with 200 molar excess NaBH₄ (Sigma Chemical Co.) for 10 min at 4°C, followed by 1 h at room temperature. The reduced AGE-BSA was then dialyzed against 1× PBS, and the protein concentration was determined as above. The chemically defined AGE, 2-furoyl-4-(5)-(2-furanylimidazole) (FFI), was synthesized and linked to BSA with 100 μM water soluble carbodiimide as described previously (8).

Iodination of AGE-BSA. AGE-BSA was iodinated with carrier-free-125I by the IODO-GEN method (Bio-Rad Laboratories of Fraker and Speck (25). Samples were dialyzed against PBS until >95% of radioactivity was TCA precipitable and the samples were iodide free.

Preparation of AGE Matrices. Six-well plates coated with rat tail collagen, type I, human fibronectin, and polylysine were purchased from Collaborative Research, Inc. (Bedford, MA). AGE matrices were produced by incubating the various matrix coated plates in 0.5 M G-6-P, at 37°C for 2–3 wk in 10 mM PBS buffer (pH 7.4), as described for AGE-BSA. Control matrices were incubated under identical conditions in buffer alone. After incubation, the plates were washed extensively with 1× PBS. The amount of adhered collagen I was determined using a hydroxyproline assay (26), while adhered fibronectin and laminin were determined by the method of Lowery et al. (27) after dissolving the matrix in 2 N NaOH at
dures (8). Briefly, MCs were grown to confluency in six-well plates formed with a minor modification of previously described procedures. The blot was washed three times with lx PBS and containing 1.5% BSA, the nitrocellulose filter was probed with the radiolabeled ligand. The membranes were then washed with ice-cold PBS. The cell monolayer was then disrupted with a tight Dounce homogenizer, pestle A, in a solution of PBS, with 10 mM EDTA and protease inhibitors, as stated above. The nuclear and organelle-enriched fractions were removed by centrifugation at 13,000 g. Membranes were then isolated from the supernatant by centrifugation at 100,000 g for 1 h at 4°C. The resulting enriched membrane fraction was solubilized in PBS, containing 1% Triton X-100 and 2 mM PMSF. The protein concentration was determined by the method of Bradford (22). This material was then used for binding and ligand blotting studies.

Binding Studies. Filter binding studies were performed according to the method of Schneider et al. (29) and Daniel et al. (30) with minor modifications. 10–20 μg of MC membrane protein was dot-blotted onto nitrocellulose filters. The nitrocellulose filters were then cut and each dot was placed in a separate well of a 24-well plate. After blocking of the filters for 1 h at 4°C in PBS containing 1.5% BSA, binding studies were initiated by adding various concentrations of radiolabeled ligand to the individual wells. At 2 h, the nitrocellulose filters were washed three times with ice-cold lx PBS, and radioactivity bound was quantitated using a scintillation counter. Scatchard analysis of the data was performed to determine the binding affinity constant and the receptor number, as described previously (31). Competition studies were performed in a similar manner to the binding studies, with the exception that the nitrocellulose filters were preincubated with the competitor for 1 h before adding the radiolabeled ligand.

Binding studies were also performed on confluent MCs in six-well plates. The studies were performed in 1 ml of RPMI 1640 at 4°C after the addition of various concentrations of radioactive ligand, as described previously (8) and above. After 2 h of binding, the radioligand-containing medium was removed, and the cells were washed with ice-cold PBS. The cell monolayer was then disrupted with 1% Triton X-100, and the cell-associated radioactivity was quantitated. Protein concentration was determined by the method of Bradford (22). Specific binding was determined in an identical manner to that described above for the filter binding assay.

Ligand Blotting. MC membrane preparations (5-μg aliquots) were subjected to electrophoresis on a nonreducing SDS-PAGE (10%), and then electroblotted onto a nitrocellulose filter, as previously described (32). After blocking for 1 h in a solution of PBS containing 1.5% BSA, the nitrocellulose filter was probed with 125I-AGE-BSA in the presence of 100-fold excess of either BSA or AGE-BSA. The blot was washed three times with lx PBS and exposed to Kodak XAR-5 film at –80°C.

Uptake and Degradation. MC uptake and degradation was performed with a minor modification of previously described procedures (8). Briefly, MCs were grown to confluence in six-well plates in DMEM containing 20% FCS and insulin. MC accumulation of radioactive ligand (AGE-BSA) was assessed by incubating cells with various concentrations of 125I-AGE-BSA, in the presence and absence of 100-fold excess of unlabeled AGE-BSA, for 4 h at 37°C. After washing the cells three times with ice-cold PBS, the cells were solubilized in 1% Triton X-100 for 45 min at room temperature, and the amount of cell-associated radioactivity was determined. Specific uptake was defined by the same criteria as used for the MC binding studies. Protein concentration was determined by the method of Bradford (22). Degradation was determined by measuring TCA-soluble radioactivity in the aspirated medium.

Proliferation Assays. Rat MCs in DMEM containing 20% FCS were plated at 105 cells/well onto flat-bottomed 96-well microtiter plates, which had been pre-coated with different amounts of either AGE-modified or unmodified matrix proteins. 24 h later, the cells were washed with lx PBS and incubated for an additional 48 h in medium containing 0.3% FCS. The cells were then labeled with 2 μCi of [3H]thymidine (Amersham Corp., Arlington Heights, IL) for 18–24 h, after which the supernatants were aspirated and the cells in each well were harvested onto glass fiber filters with an automated cell harvester. The amount of [3H]thymidine incorporated was determined with a scintillation counter (Beckman Instruments). To confirm thymidine incorporation data, parallel studies were carried out using an immunocytochemical assay system for detection of DNA synthesis by measuring bromo-deoxyuridine (BrdU) incorporation (33), while in separate experiments, cells were trypsinized and counted in a particle counter (Coulter Electronics, Hialeah, FL). The data obtained by these two additional methods were consistent with [3H]thymidine results (variations between replicate wells deviated no more than 10%).

Fibronectin Production. Human MCs in RPMI 1640 supplemented with 20% FCS were plated at 2 × 105 cells per well onto six-well plates that had been coated with glucose-modified or unmodified matrix proteins. After 24 h, the cells were washed with lx PBS and incubated in medium containing 0.3% FCS for 48 h. The cells were then labeled in methionine-free medium for 3 h with 200 μCi of 35S-methionine and cysteine (Translabel; ICN, Plainview, NY). After labeling, the medium was removed and the cell monolayers were washed with cold lx PBS. The monolayers were extracted with 0.5 ml of a 1-M urea solution containing 1 mM dithiothreitol (DTT), 10 mM Tris-HCl (pH 7.4), 10 mM EDTA, and 2 mM PMSF, as previously described (34, 35). Fibronectin was then isolated from the medium and matrix by immunoprecipitation with an IgG purified anti-human fibronectin antibody (Cappel Laboratories, Malvern, PA). Anti-fibronectin antibody was added to the samples and incubated overnight at 4°C. To insure that any differences in fibronectin synthesis were not due to different number of cells/well, equal amounts of TCA-precipitable counts were immunoprecipitated from each well. The immune complexes were isolated using protein A-Sepharose beads (Pharmacia Fine Chemicals, Piscataway, NJ). After washing the protein A-Sepharose beads three times in 100 mM Tris HCl (pH 7.4), 0.5% SDS, 0.5% Triton X-100, 2 mM PMSF, and 10 mM EDTA, fibronectin was released by heating at 100°C for 5 min in SDS-PAGE sample buffer, and analyzed by gel electrophoresis and fluorography. The amount of fibronectin from each sample was quantitated by slicing the fibronectin band from the gel and determining 35S-methionine and cysteine incorporation in a liquid scintillation counter.

Results

AGE-binding Site. Membrane extracts isolated from both rat and human cultured MCs were found to contain binding
sites for AGE-modified proteins, using AGE-BSA as a model radioligand (Fig. 1). When MC membrane extracts were incubated with increasing concentrations of 125I-AGE-BSA, specific binding increased in a saturable fashion. Half-maximal binding was observed at a concentration of AGE-BSA of ~150 nM. Analysis of the specific binding data by Scatchard analysis indicated that both rat and human MCs displayed similar binding characteristics. Assuming that each labeled AGE-BSA molecule can bind to only a single receptor site, the number of AGE molecules bound per cell ranged at 3.0 ± 0.25 × 10^5 molecules per cell with a binding affinity constant of 2.0 ± 0.40 × 10^6 M^{-1} (K_d = 500 nM). Similar results were also obtained when binding studies were performed on intact cells at 4°C (data not shown).

To confirm that AGE modification of BSA was responsible for binding onto MC surface, competitive inhibition experiments were performed using either rat or human MC membrane extracts (Fig. 2). These experiments confirmed that AGE modification of the protein was responsible for binding, since excess cold AGE-BSA (Fig. 2, Ab and Bb), but not unmodified BSA (Fig. 2, Aa and Ba), could competitively inhibit >80% of 125I-AGE-BSA binding to MC membrane extracts. In addition, other AGE proteins, including AGE ribonuclease (Fig. 2, Ae and Be) and AGE collagen I (Fig. 2 Ah), successfully inhibited 125I-AGE-BSA binding to MC membrane extracts. In sharp contrast, excess unmodified ribonuclease and collagen I failed to compete for binding (Fig. 2, Af, Bf, and Ag).

To eliminate the possibility that early glycosylation products were responsible for ligand binding, AGE-BSA preparations were subjected to reduction using NaBH₄. This agent effectively reduces the Schiff base and Amadori products to glucitollysine. The ability of reduced AGE-BSA to still compete effectively for 125I-AGE-BSA binding to MC membrane extracts suggests that the ligand binding activity is due to moieties other than Amadori products, such as intermediate and advanced glycosylation adducts (Fig. 2, Ac and Bc). The ability of the chemically synthesized AGE (FFI) to inhibit ligand binding was also assessed. While FFI-BSA has been shown to bind to the macrophage AGE receptor, no competitive inhibition was exhibited by FFI-BSA for 125I-AGE-BSA binding to MC membrane extracts (Fig. 2, Ad and Bd). In this context, the MC receptor appears different from the mac-
Figure 3. (A) Uptake and degradation of 125I-AGE-BSA by rat MCs. MCs were incubated with various concentrations of 125I-AGE-BSA for 4 h at 37°C. The amount of cell-associated 125I-AGE-BSA (uptake), and the amount of TCA-soluble counts in the medium (degradation) were determined in triplicate wells. (B) Accumulation of 125I-AGE-BSA vs. time. MCs in each well were incubated with 20 µg of 125I-AGE-BSA at 37°C, and specific cell-associated radioactivity was determined at various time intervals. Cellular accumulation of radioactivity is expressed as the percent of the maximal accumulation of 125I-AGE-BSA.

Figure 4. Ligand blot analysis of enriched human MC membranes. 10 µg of solubilized membrane protein was subjected to electrophoresis on a nonreducing SDS/polyacrylamide gel (10%). The proteins in the gel were electroblotted onto nitrocellulose membrane and probed with 125I-AGE-BSA in the presence of 100-fold excess of either BSA (lane a) or AGE-BSA (lane b). The analysis presented is one of four identical experiments.
Figure 5. Effects of AGE-matrices on [3H]thymidine incorporation by MCs. Rat MCs were plated onto various matrices (10 μg/ml), as described: (a) fibronectin, (b) AGE-fibronectin, (c) collagen I, (d) AGE-collagen I, (e) laminin, (f) AGE-laminin. The results are expressed as the means ± SEM of six experiments and are expressed as the percent of [3H]thymidine incorporated relative to the control value, with control representing [3H]thymidine incorporated by cells plated on plastic.

Figure 6. Effect of AGE matrices on fibronectin synthesis by MCs. Human MCs were plated onto either unmodified or AGE-modified matrices and labeled with [35S]-methionine and cysteine, as described. The amount of fibronectin released into the medium (A), and incorporated into the matrices (B), was determined by immunoprecipitation. The fibronectin bands on the gel were excised and counted for radioactivity. The values shown are expressed as the percent increase in fibronectin produced by cells plated on the AGE matrices relative to that produced by cells plated on control unmodified matrices. The values show cpm/well and represent the means ± SEM from four experiments. (a) Fibronectin, (b) polylysine, (c) collagen I.

Discussion

The results of this study indicate that both human and rat MCs express binding sites that selectively recognize glucose-modified proteins. Evidence in favor of the existence of these sites includes several findings: MC membranes are able to bind AGE-BSA, a model ligand, in a saturable fashion, exhibiting half-maximal binding at a concentration of AGE-BSA of ~150 μM. Binding of AGE-BSA to MCs is specific for the AGE adduct, since several AGE-modified proteins, but not unmodified proteins, compete for binding. In addition, NaBH4-reduced AGE-BSA effectively competes for binding of AGE-BSA to MCs. This argues against (although not completely excludes) the notion that the binding domain is related to an early product of nonenzymatic glycosylation, since the treatment of AGE-BSA with NaBH4 reduces both the Schiff base and Amadori products to glucitolysine. Finally, ligand blotting studies confirmed the presence of three membrane proteins with molecular masses of ~50, ~40, and ~30 kD that specifically bind AGE-BSA.

In addition to binding AGE-BSA, MCs also appear to participate in both the uptake and degradation of AGE-BSA at 37°C. This is supported by several lines of evidence. First, MCs exposed to radiolabeled AGE-BSA at 37°C accumulate two- to fourfold more radioactivity than cells incubated at 4°C for the same period of time. Further evidence for the internalization of AGE-BSA is derived by comparison of the binding curves at 4°C and 37°C. At 4°C, MCs bind AGE-BSA in a saturable fashion. However, at 37°C, MCs continue to accumulate [125I]-AGE-BSA in a nonsaturable manner up to concentrations of AGE-BSA as high as 1.1 μM. This increase in cell-associated radioactivity at 37°C could be attributed to slow internalization of the AGE receptor complex with subsequent recycling of the receptors back to the cell surface after the intracellular release of AGE-BSA. A similar
been reported in the diabetic kidney, we were first interested in assessing whether plating MCs on AGE matrices could stimulate MC proliferation. In contrast to the increase in MC number which has been reported in the diabetic kidney (3), MCs plated on AGE matrices exhibited a decrease in proliferation as measured by \(^{3}H\) thymidine incorporation. Crowley et al. (40) also found that MC proliferation was inhibited when MCs were grown on MC-generated matrices that had been nonenzymatically glycosylated with glycoaldehyde. One possibility that could account for the discrepancy between this in vitro result and in vivo findings is that MC proliferation in vivo is not mediated by a direct interaction of AGE matrix proteins with MCs. In vivo, the interaction of MCs with other components of the glomerular mesangium, such as blood-derived macrophages, could provide a paracrine proliferative stimulus to MCs in the diabetic kidney.

The interaction of macrophages with AGEs has been shown to induce the release of a variety of cytokines, such as cachectin/TNF and IL-1, which could have paracrine growth-promoting effects on MC in vivo (14).

Increased mesangial accumulation of fibronectin has been noted in humans and experimental animals with diabetic kidney disease (4, 5). In addition, the presence of elevated fibronectin mRNA levels in kidneys from diabetic animals (41) indicates that enhanced synthesis of fibronectin accounts for at least part of the increased accumulation. The observation that the interaction of MCs with AGE matrices in vitro induces an increase in fibronectin secretion suggests that in vivo, the interaction of MCs with AGE-modified matrices may stimulate MCs to enhance synthesis of this important matrix component.

Recent experimental findings have documented the importance of ambient glucose concentration in modulating cell function (42-44). Incubation of MCs in high glucose medium leads to a diminished rate of proliferation, along with increased production of several matrix proteins, including fibronectin, collagen IV, and laminin. The findings reported here provide an additional mechanism by which elevated glucose levels, acting through AGE modification of matrix proteins, may alter MC function. In addition, it is possible that some of the functional alterations detected in the elevated glucose environment may actually have resulted from AGE modification of existing matrix proteins, since a time delay of several days in high glucose medium was necessary before alterations in MC function became apparent.

The upregulation of fibronectin mRNA in kidneys from diabetic animals has been found to persist for several weeks after the restoration of normoglycemia (41). Since the formation of AGEs occurs in an irreversible fashion, it follows that the “memory” of a prior elevated glucose concentration should persist in the form of AGE moieties within long-lived matrix proteins. The continued interaction of these matrix proteins with MCs, despite restoration of normoglycemia, may be one of the stimuli for MCs to continue producing fibronectin. This finding may also help to explain the difficulty encountered in treating clinical diabetic kidney disease. Once kidney disease has occurred, controlling of ambient glucose concentration does little to avert the progression of disease (45). While many mechanisms undoubtedly contribute to this phenomenon, the continued interaction between AGE-modified matrix proteins and kidney MCs may contribute to the progressive functional abnormalities, despite normalization of blood glucose levels.

At present it is not clear whether the alteration in MC function associated with exposure to AGE matrices is mediated via the MC AGE-binding sites. In this regard, we have been unable to demonstrate these functional alterations using a soluble AGE ligand. However, it is known that the ability
of a ligand to crosslink its receptor may be critical for signal transduction (46). While soluble ligands may not be able to perform this function, ligands adhering to a cell surface acquire the ability to crosslink their receptor. This phenomenon could provide one mechanism whereby AGE matrices could interact with AGE receptors, while soluble AGE ligands can not.

Alternatively, it is possible that the formation of AGEs on matrix proteins may affect MC function by altering normal matrix-matrix and matrix-cell interactions distinct from the AGE receptor pathway. The formation of AGEs on matrix proteins results in protein crosslinking that could cause the distortion of important protein recognition sites through mechanisms unrelated to the AGE receptors. The binding of anionic proteoglycans, such as heparin sulfate, to matrix proteins is reduced after AGE modification (47). Similarly, the ability of fibronectin to bind collagen is impaired after AGE modification (48). These effects of glycosylation may alter the composition of matrix. Matrix proteins are also able to interact with distinct receptors on MCs, and this interaction is important in the regulation of cell adhesion, cell growth, and gene expression (49). Glycosylation of matrix proteins may alter their recognition by cellular receptors. It is therefore conceivable that nonenzymatic glycosylation of normal matrix proteins, by altering normal matrix composition and/or distorting normal cellular recognition sites for matrix proteins, may produce some of the functional changes observed in MC phenotype.

The studies reported here represent the identification and initial characterization of mesangial cell surface binding proteins that recognize AGE proteins, and provide a mechanistic basis whereby AGE-modification of matrix proteins in the kidney may lead to alterations of MC function. We demonstrated that MCs plated on AGE-modified matrices exhibit altered functional characteristics, including enhanced production of fibronectin and decreased proliferation. Many questions remain to be addressed; in particular, the relationship between AGE receptors reported on different cell types, and the relationship of the MC AGE-binding proteins to other known MC receptors remain to be elucidated. We can now begin to explore the range of biological effects that may be modulated via these molecules, and to investigate the in vivo role that they may play in maintaining normal kidney homeostasis. Finally, we can begin to assess the degree to which these receptors may contribute to the development of diabetic renal complications.

We are grateful to Dr. Michael Ganz (Yale University) for his assistance in preparing rat mesangial cells, and Drs. J. Floege and K. Resch (Hannover, Germany) for providing the human mesangial cells.

This work was supported in part by National Institutes of Health grants DK-01927 to E. Skolnik and AG-6943 to H. Vlassara. M. Kirstein is a fellow of the New York State Health Research Council.

Address correspondence to Helen Vlassara, The Picower Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030.

Received for publication 28 May 1991 and in revised form 1 July 1991.

References

1. Mauer, S.M., W.M. Steffes, E.N. Ellis, D.E.R. Sutherland, D.M. Brown, and F.C. Goetz. 1984. Structural-functional relationships in diabetic nephropathy. J. Clin. Invest. 74:1143.
2. Ellis, E.N., W.M. Steffes, F.C. Goetz, D.E.R. Sutherland, and S.M. Mauer. 1986. Glomerular filtration in type I diabetes mellitus. Kidney Int. 29:889.
3. Thomsen, O.F., A.R. Andersen, J.S. Christiansen, and T. Deckert. 1984. Renal changes in long term type I diabetic patients with and without clinical nephropathy: a light microscopic, morphometric study of autopsy material. Diabetologia. 26:561.
4. Brunoval, P., J.M. Foidart, D. Nochy, J.P. Camilleri, and J. Bariety. 1985. Glomerular matrix proteins in nodular gliomerulosclerosis in association with light chain deposition disease and diabetes mellitus. Hum. Pathol. 16:477.
5. Falk, R.J., J.I. Schienman, S.M. Mauer, and A.F. Michael. 1983. Polyantigenic expansion of basement membrane constituents in diabetic nephropathy. Diabetes. (Suppl. 2)32:34.
6. Brownlee, M., A. Cerami, and H. Vlassara. 1988. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318:1335.
7. Vlassara, H., M. Brownlee, and A. Cerami. 1986. Nonenzymatic glycosylation: a role in the pathogenesis of diabetic complications. Clin. Chem. 32:B37.
8. Vlassara, H., M. Brownlee, and A. Cerami. 1985. High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent proteins. Proc. Natl. Acad. Sci. USA. 82:5588.
9. Vlassara, H., J. Valinsky, M. Brownlee, C. Cerami, S. Nishimoto, and A. Cerami. 1987. Advanced glycosylation end-products on erythrocyte cell surface induces receptor-mediated phagocytosis by macrophages. J. Exp. Med. 166:539.
10. Monnier, V.M., R.R. Kohn, and A. Cerami. 1984. Accelerated age-related browning of human collagen in diabetes mellitus. Proc. Natl. Acad. Sci. USA. 81:583.
11. Makita, Z., S. Radoff, E. Rayfield, A. Cerami, E. Friedman, and H. Vlassara. 1990. Radioreceptor assay for human serum and arterial tissue advanced glycosylation endproducts. Diabetes. 39:29A.
12. Vlassara, H., M. Brownlee, K. Manogue, C. Dinarello, and A. Pasagian. 1988. Cachectin/TNF and IL-1 induced by glucose-modified proteins: a role in normal tissue remodeling. Science (Wash. DC). 240:1546.
13. Esposito, C., H. Gerlach, J. Brett, D. Stern, and H. Vlassara.
1989. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. *J. Exp. Med.* 170:1387.
14. Kirstein, M., J. Brett, S. Radoff, S. Ogawa, D. Stern, and H. Vlassara. 1990. Advanced protein glycosylation induces selective transendothelial human monocyte chemotaxis and secretion of PDGF: Role in vascular disease of diabetes and aging. *Proc. Natl. Acad. Sci. USA.* 87:9010.
15. Kirstein, M., C. Aston, and H. Vlassara. 1990. Normal human monocytes express insulin-like growth factor 1 (IGF-1) in response to matrix glycation: role in tissue remodelling. *FASEB J.* 4:1759A.
16. Schondorff, D. 1987. The glomerular mesangial cell: an expanding role for a specialized pericyte. *FASEB J.* 1:1272.
17. Lovett, D.H., and R.B. Sterzel. 1986. Cell culture approaches to the analysis of glomerular inflammation. *Kidney Int.* 30:246.
18. Striker, G.E., and L.J. Striker. 1985. Glomerular cell culture. *Lab Invest.* 53:122.
19. Lovett, D.H., J.L. Ryan, and R.B. Sterzel. 1983. Stimulation of rat mesangial proliferation by macrophage interleukin 1. *J. Immunol.* 131:2830.
20. Weber, H.I., S.N. Emancipator, M.L. Tykocinski, and J.R. Sedor. 1987. The interleukin 1 gene is expressed by rat glomerular mesangial cells and is augmented in immune complex glomerulonephritis. *J. Immunol.* 138:3207.
21. Radeke, H.H., B. Meier, N. Topley, J. Floege, G.G. Habermehl, and K. Resch. 1990. Interleukin-1 and tumor necrosis factor induce oxygen radical release of cultured human glomerular mesangial cells. *Kidney Int.* 37:767.
22. Bradford, M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* 72:248.
23. Kohn, R.A., A. Cerami, and V. Monnier. 1984. Collagen aging and its lipoprotein receptor. *Proc. Natl. Acad. Sci. USA.* 85:9228.
24. Radoff, S.J., J.A. Katzmann, R.M. Currie, E.L. Evans, D.W. Houck, B.C. Kline, P.R. Greipp, and M.R. Loken. 1986. S-phase detection with an antibody to bromodeoxyuridine. Role of DNase pretreatment. *J. Immunol. Methods.* 93:97.
25. Mackay, K., J.L. Striker, J.W. Stauffer, T. Doi, L.Y. Agodoa, and G.E. Striker. 1989. Transforming growth factor beta: mingle glomerular receptors and responses of isolated glomerular cells. *J. Clin. Invest.* 83:1160.
26. Wasserman, J., A. Santiago, V. Rifici, H. Holthofer, L. Scharschmidt, M. Epstein, and D. Schondorff. 1989. Interaction of low density lipoprotein with rat mesangial cells. *Kidney Int.* 35:1168.
27. Lowry, O.H., N.J. Rosebrough, A.L. Farr, and R.J. Randall. 1951. Protein measurement with the folin phenol reagent. *J. Biol. Chem.* 193:265.
28. Sutherlin, H., and R.B. Sterzel. 1986. Cell culture approaches to the analysis of glomerular inflammation. *Kidney Int.* 30:246.
29. Schneider, W.J., J.L. Goldstein, and M.S. Brown. 1979. Solubilization of low density lipoprotein receptor. *Proc. Natl. Acad. Sci. USA.* 76:5577.
30. Daniel, T.O., W.J. Schneider, J.L. Goldstein, and M.S. Brown. 1983. Visualization of lipoprotein receptors by ligand blotting. *J. Biol. Chem.* 258:4606.
31. Scatchard, G. 1949. The attraction of proteins for small molecules and ions. *Ann. NY Acad. Sci.* 51:660.
32. Kodama, T., P. Reddy, C. Kishimoto, and M. Krieger. 1988. Purification and characterization of a bovine acetyl Low density lipoprotein receptor. *Proc. Natl. Acad. Sci. USA.* 85:9228.
33. Gotcheroff, N.J., J.A. Katzmann, R.M. Currie, E.L. Evans, D.W. Houck, B.C. Kline, P.R. Greipp, and M.R. Loken. 1986. S-phase detection with an antibody to bromodeoxyuridine. Role of DNase pretreatment. *J. Immunol. Methods.* 93:97.
34. Igniz, R.A., and J. Massague. 1986. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. *J. Biol. Chem.* 261:4337.
35. Radoff, S., A. Cerami, and H. Vlassara. 1990. Isolation of a surface binding protein specific for advanced glycosylation end-products from mouse macrophage-derived cell line RAW 264.7. *Diabetes.* 39:1510.
36. Schreiner, G.F., and E.R. Unanue. 1984. Origin of the rat mesangial phagocyte and its expression of the leukocyte common antigen. *Lab Invest.* 51:515.
37. Scatchard, G. 1949. The attraction of proteins for small molecules and ions. *Ann. NY Acad. Sci.* 51:660.
38. Kohn, R.A., A. Cerami, and V. Monnier. 1984. Collagen aging and its lipoprotein receptor. *Proc. Natl. Acad. Sci. USA.* 85:9228.
39. Vlassara, H., L. Moldawer, and B. Chan. 1989. Macrophage/mesangial cell for nonenzymatic glycosylated proteins is up-regulated by cachectin/tumor necrosis factor. *J. Clin. Invest.* 84:1813.
40. Crowley, S., M. Brownlee, D. Edelstein, P. Singhal, J. Satiano, T. Morl, and D. Schondorff. 1991. Effects of nonenzymatic glycosylation of mesangial cell matrix on proliferation of mesangial cells. *Diabetes.* 40:540.
41. Roy, S., R. Sala, E. Caglierio, and M. Lorenzi. 1990. Overexpression of fibronectin induced by diabetes or high glucose: Phenomenon with a memory. *Proc. Natl. Acad. Sci. USA.* 87:404.
42. Kreisberg, J., R.A. Radnick, S.H. Ayo, J. Garoni, E.R. Rampt, and D.R. Applin. 1990. Increased fibronectin synthesis and expression of mRNA in mesangial cells cultured in high glucose medium. *Kidney Int.* 37:220A.
43. Kreisberg, J., S. Ayo, W. Glass, R. Radnick, and J. Garoni. 1989. Effect of high glucose on extracellular matrix protein accumulation in cultured mesangial cells. *FASEB J.* 3:445A.
44. Nahman, N.S. Jr., K. Leonart, and F.G. Cosio. 1990. Effects of high glucose concentration on human mesangial cell growth and fibronectin production. *Kidney Int.* 37:221A.
45. The DCCT Research Group. 1988. Are continuing studies of metabolic control and microvascular complications in insulin-dependent diabetes mellitus justified? The diabetes control and complications trial. *N. Engl. J. Med.* 318:246.
46. Brownlee, M., H. Vlassara, and A. Cerami. 1987. Aminoguanidine prevents the hyperglycemia-induced defect in binding of heparin by matrix molecules. *Diabetes.* 36:(Suppl.1):85A.
47. Brownlee, M., H. Vlassara, and A. Cerami. 1987. Aminoguanidine prevents the hyperglycemia-induced defect in binding of heparin by matrix molecules. *Diabetes.* 36:(Suppl.1):85A.
48. Tarsio, J.F., R.B. Wigness, W.M. Rupp, H. Buchwald, and L.T. Furcht. 1985. Nonenzymatic glycation of fibronectin and alterations of cell matrix and basement membrane components in diabetes mellitus. *Diabetes.* 34:477.
49. Simonson, M.S., L.A. Culp, and M.J. Dunn. 1989. Rat mesangial cell-matrix interaction in culture. *Exp. Cell Res.* 184:484.

939 Skolnik et al.